WO1998017253A1 - Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale - Google Patents
Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale Download PDFInfo
- Publication number
- WO1998017253A1 WO1998017253A1 PCT/US1997/019343 US9719343W WO9817253A1 WO 1998017253 A1 WO1998017253 A1 WO 1998017253A1 US 9719343 W US9719343 W US 9719343W WO 9817253 A1 WO9817253 A1 WO 9817253A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- inhibitor
- inhibitors
- synthesis
- ceramide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- Conduritol B epoxide an inhibitor of ⁇ glucocerebrosidase, applied with fluindostatin very significantly increased stratum corneum water permeability but when combined with TOFA a significant increase in water permeability resulted.
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49193/97A AU4919397A (en) | 1996-10-23 | 1997-10-22 | Method and compositions for disrupting the epithelial barrier function |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73371296A | 1996-10-23 | 1996-10-23 | |
US08/733,712 | 1996-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998017253A1 true WO1998017253A1 (fr) | 1998-04-30 |
Family
ID=24948821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/019343 WO1998017253A1 (fr) | 1996-10-23 | 1997-10-22 | Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4919397A (fr) |
WO (1) | WO1998017253A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001011009A2 (fr) * | 1999-07-23 | 2001-02-15 | Gauldie, Jack | Therapie genique intestinale |
EP1534213A2 (fr) * | 2002-03-13 | 2005-06-01 | Collagenex Pharmaceuticals, Inc. | Systemes d'administration a base aqueuse |
WO2008058034A1 (fr) * | 2006-11-03 | 2008-05-15 | Qlt Inc. | Procédés de traitement de troubles ou d'affections dermatologiques |
US7825104B2 (en) * | 2001-07-23 | 2010-11-02 | Ramot At Tel Aviv University Ltd. | Methods and compositions for treating fungal infections |
JP2012521376A (ja) * | 2009-03-25 | 2012-09-13 | コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | クエン酸カルシウムおよびn−アシル化アミノアルコール誘導体を含んでなる乾燥皮膚および皮膚老化の兆候を防ぐための化粧品組成物 |
US8884034B2 (en) | 2009-07-08 | 2014-11-11 | Dermira (Canada), Inc. | TOFA analogs useful in treating dermatological disorders or conditions |
US10406088B2 (en) | 2015-01-20 | 2019-09-10 | TetraDerm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021230A1 (fr) * | 1993-03-19 | 1994-09-29 | Cellegy Pharmaceuticals, Inc. | Procedes et compositions permettant de desorganiser le fonctionnement de la barriere epitheliale |
-
1997
- 1997-10-22 AU AU49193/97A patent/AU4919397A/en not_active Abandoned
- 1997-10-22 WO PCT/US1997/019343 patent/WO1998017253A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021230A1 (fr) * | 1993-03-19 | 1994-09-29 | Cellegy Pharmaceuticals, Inc. | Procedes et compositions permettant de desorganiser le fonctionnement de la barriere epitheliale |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001011009A2 (fr) * | 1999-07-23 | 2001-02-15 | Gauldie, Jack | Therapie genique intestinale |
WO2001011009A3 (fr) * | 1999-07-23 | 2002-09-12 | Gauldie Jack | Therapie genique intestinale |
US7825104B2 (en) * | 2001-07-23 | 2010-11-02 | Ramot At Tel Aviv University Ltd. | Methods and compositions for treating fungal infections |
EP1534213A2 (fr) * | 2002-03-13 | 2005-06-01 | Collagenex Pharmaceuticals, Inc. | Systemes d'administration a base aqueuse |
EP1534213A4 (fr) * | 2002-03-13 | 2005-10-26 | Collagenex Pharm Inc | Systemes d'administration a base aqueuse |
US8029810B2 (en) | 2002-03-13 | 2011-10-04 | Thomas Skold | Water-based delivery systems |
WO2008058034A1 (fr) * | 2006-11-03 | 2008-05-15 | Qlt Inc. | Procédés de traitement de troubles ou d'affections dermatologiques |
JP2012521376A (ja) * | 2009-03-25 | 2012-09-13 | コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | クエン酸カルシウムおよびn−アシル化アミノアルコール誘導体を含んでなる乾燥皮膚および皮膚老化の兆候を防ぐための化粧品組成物 |
US8884034B2 (en) | 2009-07-08 | 2014-11-11 | Dermira (Canada), Inc. | TOFA analogs useful in treating dermatological disorders or conditions |
US9434718B2 (en) | 2009-07-08 | 2016-09-06 | Dermira (Canada), Inc. | TOFA analogs useful in treating dermatological disorders or conditions |
US9782382B2 (en) | 2009-07-08 | 2017-10-10 | Dermira (Canada), Inc. | TOFA analogs useful in treating dermatological disorders or conditions |
US10406088B2 (en) | 2015-01-20 | 2019-09-10 | TetraDerm Group LLC | Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration |
Also Published As
Publication number | Publication date |
---|---|
AU4919397A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6190894B1 (en) | Method and compositions for disrupting the epithelial barrier function | |
US6010691A (en) | Methods for enhancing permeation of a topically administered physiologically active substance | |
US5993836A (en) | Topical anesthetic formulation | |
WO1994021230A1 (fr) | Procedes et compositions permettant de desorganiser le fonctionnement de la barriere epitheliale | |
US7109246B1 (en) | Pharmaceutical compositions comprising an amphoteric surfactant an alkoxylated cetyl alcohol and a polar drug | |
CN100482216C (zh) | 氢氧根释放剂增强透皮渗透的用途 | |
KR100217258B1 (ko) | 경비조성물 | |
EP0129285A2 (fr) | Compositions pharmaceutiques topiques pénétrantes contenant de la N-(2-hydroxyéthyl)-pyrrolidone | |
US20040101582A1 (en) | Treatment of neuropathy | |
JP2003532629A (ja) | 第4アンモニウム塩の経皮薬剤放出への使用 | |
US20120149779A1 (en) | High concentration local anesthetic formulations | |
US9308203B2 (en) | Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis | |
JP2008506767A (ja) | 発毛を刺激する製剤 | |
US6894078B2 (en) | Alcohol based topical anesthetic formulation and method | |
JP2007531694A (ja) | 局所適用医薬組成物 | |
IL109036A (en) | Preparations for detachment of the epithelial barrier function and use of means for the preparation of such preparations | |
JPH05178764A (ja) | 局所用あるいは経皮用製品におけるジブチルアジペートとイソプロピルミリステートの用途 | |
US5932227A (en) | Percutaneously administrable base composition and drug composition prepared therefrom | |
EP0216303B1 (fr) | Médicament à usage externe | |
WO1998017253A1 (fr) | Procede et compositions utilises pour interrompre la fonction de la barriere epitheliale | |
WO1996025154A1 (fr) | Formulation transdermique | |
GB2497728A (en) | Statin formulations for transmucosal delivery | |
WO1996025042A1 (fr) | Formulation transdermique | |
EP0764017A1 (fr) | Procedes et compositions permettant d'induire une separation de phase dans des doubles couches lipidiques epitheliales | |
US9744156B2 (en) | Methods and compositions for enhanced transungual delivery of AR-12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |